Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sorrento Therapeutics, Inc. - Common Stock (NQ: SRNE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sorrento Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Market Briefing For Tuesday, Sept. 14
Inflation and COVID are tied at the hip in this market and economic scenario. I assessed inflation as 'enduring and not transitory' all along, and where COVID comes into-play is as a 'spoiler' to... 
Via Talk Markets
Market Briefing For Tuesday, Sept. 7
Economists are too worried about what's happening under the hood of the economic engine; when they really should realize all that's needed will be effective treatments and better vaccines to 'fuel' the... 
Via Talk Markets
Market Briefing For Thursday, Sept. 2
Near parabolic uptrends exist for the S&P and the Nasdaq, encouraging bulls, who should know better regarding 'finalized phasing' of runs but there's no assurance of a repeat phase of similar moves... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Market Briefing For Wednesday, Sept. 1
Nuances and ambiguities dominate the market and even geopolitical scene at the moment. We are going to have hotter inflation than the Fed would like, but growth does matter, because we concurrently... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Market Briefing For Wednesday, Aug.25
The stock market holds, pretty impressive ahead of 'virtual Jackson Hole', and it faded late in the day just as we thought likely for the late going. 
Via Talk Markets
Market Briefing For Tuesday, Aug. 31
Moderate selling was masked in Monday's market, and it's against a clear backdrop of a stretched market, and even month-end pension sales, related to clients of Goldman Sachs raising 13B. The strength... 
Via Talk Markets
Why Shares of Sorrento Therapeutics Jumped This Week
The clinical-stage biopharmaceutical company published promising news in two separate studies. 
Via The Motley Fool
Sorrento's mRNA COVID-19 Vaccine Shows Efficacy In Preclinical Study
Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced preclinical results for its mRNA-based COVID-19 vaccine against SARS-CoV-2. STI-mRNA includes a proprietary designer Spike... 
Via Benzinga
Exposures COVID-19
Market Briefing For Thursday, Aug. 26
Underperformance by many stocks, but few that are really in trouble, is reflective of rising complacency, while technicians are frustrated at the lack of breakouts or breakdowns. That's actually fine,... 
Via Talk Markets
Sorrento In-Licenses COVID-19 Targeted MPro Inhibitors
Sorrento Therapeutics Inc (NASDAQ: SRNE) has entered into an option agreement with The Texas A&M University System for exclusive rights to highly... 
Via Benzinga
Exposures COVID-19
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Exposures COVID-19 Interest Rates Product Safety
Market Briefing For Tuesday, Aug. 24
Suspended elevation of the S&P may be in-absence of any alternatives to do so, given what pretty much would be a 'snapping' of the short-term uptrend if that's broken. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
Market Briefing For Monday, Aug. 23
We might be near a moment of truth for the Senior Indexes, either in just a few days or postponed until after Labor Day. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares... 
Via Benzinga
Market Briefing For Tuesday, Aug. 17
Momentum grows for a Fed taper. Investor risk now is no more than just a couple weeks ago. Actually a Fed movement is a plus as it suggest they're a believe in economic growth; which will be favorable... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Market Briefing For Monday, Aug. 16
Too many permabears are almost delirious with negativity and still give extremely bearish outlooks, when that's not a correct read of markets. 
Via Talk Markets
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Why Dynavax, Novavax, and Sorrento Soared This Week
There were different reasons behind each of these COVID-19 vaccine stocks' big gains. 
Via The Motley Fool
Exposures COVID-19
Market Briefing For Thursday, Aug. 12
Fear and hysteria are not engineered by Washington about COVID, however it is a 'mood' to factor into everything from media to stock market projections. 
Via Talk Markets
Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses
Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to... 
Via Benzinga
Market Briefing For Tuesday, Aug. 10
Most markets held gains as the total backdrop has not changed. Lots of money managers are eager to see a decline, to put more money 'in', but the market hasn't cooperated by dropping 'much'. 
Via Talk Markets
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Thinking About Buying Stock In AMD, General Motors Or Sorrento Therapeutics?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Market Briefing For Monday, Aug. 9
Ultimately energy markets will envision post-pandemic era robust economic activity resuming, even though Covid surges temporarily squelch demand. 
Via Talk Markets
Cramer Advises Viewers On Palantir, SoFi And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't understand why is MKS Instruments, Inc. (NASDAQ: MKSI) trading so cheap. He would be a buyer.... 
Via Benzinga
Market Briefing For Wednesday, Aug. 4
'Subject to mandate' seems to be a catch-phrase these days; mandates to fly, to eat, to drink in a pub, to go to a show, and even to govern New York (of course that last one was an effort at humor,... 
Via Talk Markets
Market Briefing For Tuesday, Aug. 3
We do see Tuesday turnaround as a rebound from Monday's just modest fade. Again our wildcard continues to be Covid; and the 'presumed' dovish Fed as relates to 'tapering'. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.